Financial releases

Validation of the ZENEO® Midazolam clinical batch

Good Manufacturing Practices certificate issued by the ANSM

First-half 2021 results and business update

US & Canada licensing agreement with Eton Pharmaceuticals for Crossject’s ZENEO® Hydrocortisone

2020 Annual results and business update

Crossject benefits from The French National Recovery Plan, with a €1.5 million grant

Crossject successfully raises €12 million in funding

First-half 2020 results and business update

Annual report 2019

End of the conversion of convertible bonds issued in 2019